Corcept Therapeutics
CORT
208 hedge funds and large institutions have $1.03B invested in Corcept Therapeutics in 2019 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 61 increasing their positions, 78 reducing their positions, and 41 closing their positions.
2.49% less ownership
Funds ownership: 78.8% → 76.31% (-2.5%)
6% less funds holding
Funds holding: 222 → 208 (-14)
22% less repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 78
29% less first-time investments, than exits
New positions opened: 29 | Existing positions closed: 41
39% less call options, than puts
Call options by funds: $5M | Put options by funds: $8.24M
44% less capital inflows, than outflows
Capital inflows: $55.2M | Capital outflows: $99.5M
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$5.1M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$5.02M |
| 3 |
BlackRock
New York
|
+$3.97M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$2.55M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$2.53M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
-$30.6M |
| 2 |
D.E. Shaw & Co
New York
|
-$6.44M |
| 3 |
Morgan Stanley
New York
|
-$5.63M |
| 4 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
-$5.39M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$5.32M |
CORT Hedge Fund Activity: Q1 2019 in Review
208 of the 4,634 institutional investors tracked by Wall St. Rank reported a position in Corcept Therapeutics (CORT) for Q1 2019, worth a combined $1.03B — down 15% from $1.22B a quarter earlier.
Sellers outnumbered buyers: 41 funds closed out of CORT and 29 opened new positions — a net loss of 12 holders — while 78 trimmed existing stakes and 61 added.
The largest buyer was Renaissance Technologies, adding an estimated $5.1M. The largest seller was Consonance Capital Management, cutting an estimated $30.6M.
- 208 institutional investors held Corcept Therapeutics (CORT) as of Q1 2019, down from 222 in Q4 2018.
- Funds reported $1.03B of Corcept Therapeutics stock for Q1 2019, down 15% quarter-over-quarter.
- 29 funds opened new Corcept Therapeutics positions in Q1 2019 and 41 closed out, a net change of -12 holders.
- The largest Corcept Therapeutics buyer in Q1 2019 was Renaissance Technologies, an estimated $5.1M added.
- The largest Corcept Therapeutics seller in Q1 2019 was Consonance Capital Management, an estimated $30.6M sold.
Based on aggregated 13F filings for Q1 2019.